comparemela.com
Home
Live Updates
Ignacio Melero Center - Breaking News
Pages:
Latest Breaking News On - Ignacio melero center - Page 1 : comparemela.com
CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of
Spain
Germany
Switzerland
Kostenloser-wertpapierhandel
Catalym-gmb
Phil-lhuillier
Ignacio-melero-center
World-health-organization
International-nonproprietary-name
Trophic-communications
Differentiation-factor
Ted-human-effector
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
Press release content from Business Wire. The AP news staff was not involved in its creation.
Spain
Germany
Switzerland
Catalym-gmb
Phil-lhuillier
Ignacio-melero-center
World-health-organization
International-nonproprietary-name
Trophic-communications
Differentiation-factor
Ignacio-melero
Advanced-medical-research
vimarsana © 2020. All Rights Reserved.